BioSpace News Archive

Regenative Labs (Regenative), a leading HCT/P manufacturer, announces a retrospective case series demonstrating new care advancements using its Wharton’s Jelly allografts in the supplementation of Temporomandibular Joint (TMJ) defects.

Rockwell Medical, Inc. announced that the Company entered into a three-year product purchase agreement with Centers for Dialysis Care, Inc., the largest non-profit, independent outpatient dialysis provider in Northeast Ohio.

Eli Lilly and Company and POINT Biopharma Global, Inc. announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.

Aclaris Therapeutics, Inc. today announced the completion of enrollment into ATI-1777-AD-202, its Phase 2b trial of its investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, ATI-1777, in patients with mild to severe atopic dermatitis.

Medicenna Therapeutics Corp. today announced that new preclinical data characterizing MDNA223, an anti-PD1-IL-2 BiSKIT (Bifunctional SuperKine for ImmunoTherapy), were presented at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy held from October 1 - 4, 2023, in Toronto, Canada.

Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA.

Immunoglobulin National Society announced it is partnering with the Accreditation Commission for Health Care, an internationally recognized accreditation leader that develops solutions for healthcare providers worldwide.

Rallybio Corporation today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “Novel Platform Technologies in Rare Disease and Oncology,” at the JonesTrading 2023 Healthcare Summit on October 10, 2023 at 11:00 a.m.

Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has expanded its portfolio of generic injectable products, through an asset purchase agreement by its parent company, Hong Kong King-Friend Industry Co., (HKF).

IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a strategic collaboration with argenx to advance treatment to patients with rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance (PV) safety services and solutions.